BIOSCIENCE firm Oxford Immunotec, which has developed a breakthrough test for TB, saw revenue jump 36 per cent to £19.7m, for the three months ended June 30.
The bulk of growth for the Milton Park-based company came from the United States, where revenues were up 65 per cent.
The firm is also having success with its tests for tick-borne disease.
Chief executive Dr Peter Wrighton-Smith said: “We delivered a strong second quarter with revenue growth that exceeded the top end of our guidance range.
“As we continue our evolution from a single- to a multi-product company, we are pleased to see solid growth in our core TB business as well as a strong contribution from our accelerating tick-borne disease franchise.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here